September 25 - 28, 2019
Espace Grand Arche de la Defense
Abstract submission deadline: Thursday, July 18
Advance registration deadline: Monday, July 1
Huber, Association for Cancer Immunotherapy, Mainz, GermanyGuido
Kroemer, Centre de Recherche des Cordeliers, Paris, FranceEllen
Puré, University of Pennsylvania, Philadelphia, PennsylvaniaGiorgio
Trinchieri, National Cancer Institute, Frederick, Maryland
Scientific Planning CommitteeSandra Demaria, Weill Cornell Medical College, New York, New YorkWolf Hervé Fridman, Centre de Recherche des Cordeliers, Paris, FranceNir Hacohen, Massachusetts General Hospital and Broad Institute, Cambridge, MassachusettsSebastian Kreiter, Johannes Gutenberg University, Mainz, GermanyCornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals, Leiden, The NetherlandsMiriam Merad, Icahn School of Medicine at Mount Sinai, New York, New YorkCatherine Sautès-Fridman, Université Paris-Descartes, Paris, FranceRobert D. Schreiber, Washington University School of Medicine, St. Louis, MissouriÖzlem Türeci, BioNTech AG, Mainz, GermanyE. John Wherry, Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PennsylvaniaLaurence Zitvogel, Institut Gustave Roussy, Paris, France
The Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to present the Fifth International Cancer lmmunotherapy Conference.
The 2019 meeting will be held at the Espace Grande Arche in Paris, France from September 25-28, 2019. The program will focus on "Translating Science into Survival," and feature talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: regulating T cells and their response to cancer, tumor microenvironment, genetically engineered T cells, maintenance of immune balance, novel vaccine platforms and combinations, mutational analysis and predicting response to immunotherapy, convergence of technology and cancer immunotherapy, microbiome, and metabolism.
This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.